The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Loh, Yan Ni ^a   Hedditch, Ellen L ^a   Baker, Laura A ^a   Jary, Eve ^a   Ward, Robyn L ^a   Ford, Caroline E ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Breast cancer; Endocrine resistant; Epithelial to mesenchymal transition (EMT); IWP 2; Tamoxifen resistant; Wnt signalling

Indexed keywords

BETA CATENIN; CELL MARKER; CYCLIN D1; IWP 2; MESSENGER RNA; PROTEIN INHIBITOR; TAMOXIFEN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR TWIST; TWIST 1 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; WNT3A PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AXIS INHIBITION PROTEIN 2 GENE; BREAST CANCER; CANCER RESISTANCE; CELL AGGREGATION; CELL SHAPE; CELL SIZE; CELL STRAIN MCF 7; CK1ALPHA GENE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DKK1 GENE; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; ONCOGENE C JUN; ONCOGENE MYC; PORCN GENE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROR2 GENE; TRANSCRIPTION REGULATION; UPREGULATION; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; TAMOXIFEN; UP-REGULATION; WNT SIGNALING PATHWAY;

EID: 84875505291     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-174     Document Type: Article

References (46)

1. (EBCTCG) EBCTCG Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717. (EBCTCG) EBCTCG.
2. Jordan VC. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res 2009, 69(4):1243-1254. 10.1158/0008-5472.CAN-09-0029, 19208829.
3. Jordan VC, Obiorah I, Fan P, Kim HR, Ariazi E, Cunliffe H, Brauch H. The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. Breast 2011, 20(Suppl 3):S1-11. 3521565, 22015273.
4. Kiely B, Stockler M. Meta-analysis: adjuvant tamoxifen reduces recurrence and death at 15 years in ER-positive early breast cancer. Ann Intern Med 2012, 156(6):JC3-4.
5. Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA, Jaitly N, Martens JW, Luider TM, Foekens JA. Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Molecular & cellular proteomics: MCP 2009, 8(6):1278-1294. 10.1074/mcp.M800493-MCP200, 3615609, 23560233.
6. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012, 149(6):1192-1205. 10.1016/j.cell.2012.05.012, 22682243.
7. Gabrovska PN, Smith RA, Tiang T, Weinstein SR, Haupt LM, Griffiths LR. Development of an eight gene expression profile implicating human breast tumours of all grade. Mol Biol Rep 2012, 39(4):3879-3892. 10.1007/s11033-011-1167-6, 21766182.
8. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 2010, 176(6):2911-2920. 10.2353/ajpath.2010.091125, 2877852, 20395444.
9. Klemm F, Bleckmann A, Siam L, Chuang HN, Rietkotter E, Behme D, Schulz M, Schaffrinski M, Schindler S, Trumper L. Beta-catenin-independent WNT signaling in basal-like breast cancer and brain metastasis. Carcinogenesis 2011, 32(3):434-442. 10.1093/carcin/bgq269, 21173432.
10. Incassati A, Chandramouli A, Eelkema R, Cowin P. Key signaling nodes in mammary gland development and cancer: beta-catenin. Breast Cancer Res 2010, 12(6):213. 10.1186/bcr2723, 3046427, 21067528.
11. Katoh M, Katoh M. Comparative genomics on Wnt5a and Wnt5b genes. Int J Mol Med 2005, 15(4):749-753.
12. Kohn AD, Moon RT. Wnt and calcium signaling: beta-catenin-independent pathways. Cell Calcium 2005, 38(3-4):439-446.
13. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004, 5(9):691-701. 10.1038/nrg1427, 15372092.
14. Yao H, Ashihara E, Maekawa T. Targeting the Wnt/beta-catenin signaling pathway in human cancers. Expert Opin Ther Targets 2011, 15(7):873-887. 10.1517/14728222.2011.577418, 21486121.
15. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009, 5(2):100-107. 10.1038/nchembio.137, 2628455, 19125156.
16. Kahlert UD, Maciaczyk D, Doostkam S, Orr BA, Simons B, Bogiel T, Reithmeier T, Prinz M, Schubert J, Niedermann G. Activation of canonical WNT/beta-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. Cancer Lett 2012, 325(1):42-53. 10.1016/j.canlet.2012.05.024, 22652173.
17. Vincan E, Barker N. The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis 2008, 25(6):657-663. 10.1007/s10585-008-9156-4, 18350253.
18. Doble BW, Woodgett JR. Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs 2007, 185(1-3):73-84.
19. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 2011, 27:347-376. 10.1146/annurev-cellbio-092910-154036, 21740232.
20. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139(5):871-890. 10.1016/j.cell.2009.11.007, 19945376.
21. Brabletz T. To differentiate or not - routes towards metastasis. Nat Rev Cancer 2012, 12(6):425-436. 10.1038/nrc3265, 22576165.
22. Meng F, Wu G. The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis. Cancer Metastasis Rev 2012, 31:455-467. 10.1007/s10555-012-9379-3, 22733307.
23. Shaw LE, Sadler AJ, Pugazhendhi D, Darbre PD. Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol 2006, 99(1):19-32. 10.1016/j.jsbmb.2005.11.005, 16533599.
24. Koga M, Musgrove EA, Sutherland RL. Modulation of the growth-inhibitory effects of progestins and the antiestrogen hydroxyclomiphene on human breast cancer cells by epidermal growth factor and insulin. Cancer Res 1989, 49(1):112-116.
25. Al Saleh S, Sharaf LH, Luqmani YA. Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int J Oncol 2011, 38(5):1197-1217.
26. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9(9):631-643. 10.1038/nrc2713, 19701242.
27. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002, 22(4):1172-1183. 10.1128/MCB.22.4.1172-1183.2002, 134648, 11809808.
28. Chien AJ, Conrad WH, Moon RT. A Wnt survival guide: from flies to human disease. J Invest Dermatol 2009, 129(7):1614-1627. 10.1038/jid.2008.445, 3125088, 19177135.
29. Gonzalez-Sancho JM, Aguilera O, Garcia JM, Pendas-Franco N, Pena C, Cal S, Garcia de Herreros A, Bonilla F, Munoz A. The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer. Oncogene 2005, 24(6):1098-1103. 10.1038/sj.onc.1208303, 15592505.
30. Huang K, Zhang JX, Han L, You YP, Jiang T, Pu PY, Kang CS. MicroRNA roles in beta-catenin pathway. Mol Cancer 2010, 9:252. 10.1186/1476-4598-9-252, 2955614, 20858269.
31. Yan L, Della Coletta L, Powell KL, Shen J, Thames H, Aldaz CM, MacLeod MC. Activation of the canonical Wnt/beta-catenin pathway in ATF3-induced mammary tumors. PLoS One 2011, 6(1):e16515. 10.1371/journal.pone.0016515, 3031586, 21304988.
32. Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M. Triple negative breast cancer-current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2009, 153(1):13-17. 10.5507/bp.2009.002, 19365520.
33. Licchesi JD, Van Neste L, Tiwari VK, Cope L, Lin X, Baylin SB, Herman JG. Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc. Oncogene 2010, 29(44):5923-5934. 10.1038/onc.2010.322, 3230129, 20697356.
34. Wang X, Chao L, Li X, Ma G, Chen L, Zang Y, Zhou G. Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and " triple-negative" breast cancers. Hum Pathol 2010, 41(3):401-406. 10.1016/j.humpath.2009.08.018, 19913278.
35. Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, Alles MC, Pinese M, Caldon CE, Schutte J, Gardiner-Garden M. Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One 2008, 3(8):e2987. 10.1371/journal.pone.0002987, 2496892, 18714337.
36. Chen Y, Xu J, Borowicz S, Collins C, Huo D, Olopade OI. c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells. BMC Cancer 2011, 11:246. 10.1186/1471-2407-11-246, 3141769, 21668996.
37. Butt AJ, Caldon CE, McNeil CM, Swarbrick A, Musgrove EA, Sutherland RL. Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol 2008, 630:189-205. 10.1007/978-0-387-78818-0_12, 18637492.
38. Witzel II, Koh LF, Perkins ND. Regulation of cyclin D1 gene expression. Biochem Soc Trans 2010, 38(Pt 1):217-222.
39. Sansom OJ, Reed KR, van de Wetering M, Muncan V, Winton DJ, Clevers H, Clarke AR. Cyclin D1 is not an immediate target of beta-catenin following Apc loss in the intestine. J Biol Chem 2005, 280(31):28463-28467. 10.1074/jbc.M500191200, 15946945.
40. Rowlands TM, Pechenkina IV, Hatsell S, Cowin P. Beta-catenin and cyclin D1: connecting development to breast cancer. Cell Cycle 2004, 3(2):145-148.
41. Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, Jernigan KK, Meyers KC, Hang BI, Waterson AG. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 2010, 6(11):829-836. 10.1038/nchembio.453, 20890287.
42. Jacob LS, Wu X, Dodge ME, Fan CW, Kulak O, Chen B, Tang W, Wang B, Amatruda JF, Lum L. Genome-wide RNAi screen reveals disease-associated genes that are common to Hedgehog and Wnt signaling. Sci Signal 2011, 4(157):ra4. 10.1126/scisignal.2001225, 21266715.
43. Ford CE, Ma S, Quadir A, Ward RL. The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis. Int J Cancer 2012,
44. Antoon JW, Lai R, Struckhoff AP, Nitschke AM, Elliott S, Martin EC, Rhodes LV, Yoon NS, Salvo VA, Shan B. Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. Scientific reports 2012, 2:539. 3406343, 22844580.
45. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 2006, 118(2):290-301. 10.1002/ijc.21355, 16080193.
46. Ward A, Balwierz A, Zhang JD, Kublbeck M, Pawitan Y, Hielscher T, Wiemann S, Sahin O. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 2013, 32(9):1173-1182. 10.1038/onc.2012.128, 22508479.